Role of DTIC (NSC-45388) in the chemotherapy of sarcomas.
DTIC was one of the first of several new agents evaluated by the Southwest Oncology Group (SWOG) and the M.D. Anderson Hospital and Tumor Institute (MDAH) in the therapy of adult patients with metastatic sarcomas. It yielded an overall response rate of 17%. This is similar to that seen in a review of 138 patients who represent the total number reported in either published or unpublished data. The subsequent addition of DTIC to adriamycin in several studies carried out at the MDAH and in the SWOG has increased the complete and partial remission rate over that seen with adriamycin alone, and more importantly has increased remission duration and survival. DTIC is currently used in combination with adriamycin in the first-line therapy of patients with metastatic sarcomas and should be considered for patients who have relapsed on primary therapy not including DTIC.
D002986:Clinical Trials as Topic; D003606:Dacarbazine / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D006801:Humans; D007890:Leiomyosarcoma / Q000188:drug therapy*; D009362:Neoplasm Metastasis; D012509:Sarcoma / Q000188:drug therapy*; D014226:Triazenes / Q000627:therapeutic use*; D014750:Vincristine / Q000627:therapeutic use
D014226:Triazenes; D014750:Vincristine; D003606:Dacarbazine; D004317:Doxorubicin